Indonesia's Biodiversity Data Gap: The Missing Infrastructure Behind Natural Product Discovery

This desk's earlier reports examined why Indonesia's life science sector is drawing foreign investor attention, and what it legally takes to enter the market. Underneath both stories sits a more fundamental question that gets less attention: before any drug, cosmetic, or nutraceutical can be developed from Indonesian biodiversity, someone has to know it exists, where to find it, and what it does — and that layer of infrastructure is far less developed than the biodiversity itself.

A Biodiversity Superpower, Still Largely Undocumented

Indonesia's biological wealth is not in question. Spread across more than 17,000 islands with the densest marine biodiversity on Earth, the country has been the source of nearly 1,000 distinct chemical compounds identified from marine organisms alone — spanning sponges, algae, mangroves, and marine bacteria and fungi — many with documented pharmacological activity, according to peer-reviewed natural product literature. One systematic review alone catalogued 732 original marine natural products from Indonesian waters across 94 species and 5 biological kingdoms.

Research institutions have acknowledged that Indonesia's biodiversity documentation remains scattered across dozens of disconnected repositories: national efforts such as BRIN's Indonesia Biodiversity Information Facility (InaBIF) coexist with at least 16 separate microbial culture collections alone, each holding pieces of the picture with limited interoperability. For a drug discovery team, a cosmetics formulator, or a foreign investor evaluating where to source a compound, that fragmentation is the practical bottleneck — not a lack of biodiversity, but a lack of a single place to find it.

Access Isn't as Simple as It Looks

Even once a promising organism or compound is identified, using it commercially is not a matter of simply collecting a sample. As a party to the Nagoya Protocol on Access and Benefit-Sharing (ABS) under the Convention on Biological Diversity, Indonesia exercises sovereign rights over its genetic resources. Foreign researchers and companies are required to secure Prior Informed Consent and enter into Access and Benefit-Sharing agreements before commercializing products derived from Indonesian biological material — a framework Indonesia has continued to formalize for foreign firms in recent years.

That requirement exists for good reason — it protects against biopiracy and ensures Indonesian researchers and communities share in the value created from their biological resources. But it also means foreign companies entering natural product research in Indonesia face a compliance layer, on top of a data layer, on top of the underlying science. Navigating all three at once from outside the country is difficult without an established local research network.

Structured Databases as the Missing Layer

This is the gap that platforms like the Indonesian Natural Products Library (INPL) — developed under the SciencePreneur ecosystem — are built to close. INPL is a publicly accessible database of natural materials sourced from Indonesia's marine and terrestrial biodiversity, built to accommodate research contributed by both Indonesian and foreign researchers in the form of extracts, fractions, and metabolites. Rather than focusing on a single kingdom, INPL spans animalia, plantae, protista, fungi, and monera — recording species name, sampling location, documented bioactivity, phytochemical content, and linked publications, alongside physical sample-storage records that let researchers trace a database entry back to an actual specimen.

A companion platform, CitMed, extends the same logic toward organisms with documented herbal potential across the full range of Indonesian biodiversity — plants, animals, bacteria, and fungi — making information on traditional and scientific use accessible for research, education, health, and the general public, including local names and geographic distribution alongside the scientific record.

Countries with comparable biodiversity wealth — Brazil among them — have already invested in similar national natural product databases to support drug discovery and dereplication research. Indonesia's equivalent infrastructure is younger and still consolidating, which for early movers is precisely the point: the organizations building and populating these databases today are shaping which compounds, and which partners, are positioned to lead as the sector matures.

Why This Matters Beyond the Lab

For pharmaceutical, cosmetic, and nutraceutical companies scouting new active compounds, a structured, ABS-compliant biodiversity database shortens the distance between raw biological material and a viable research pipeline. It also de-risks sourcing: working through an established Indonesian research network with documented provenance and existing regulatory relationships reduces the chance of a compliance misstep that could unwind years of development work.

This is the layer SciencePreneur occupies across its broader portfolio. Alongside INPL and CitMed, SciencePreneur operates as an integrated sciencepreneurship platform — anchored by PT Sciencepreneur Indonesia Gemilang, an Indonesian-capital (PMDN) life science company — connecting scientific experts, industry, and communities through consultation, commercialization support, GMP laboratory development, and a curated marketplace for science-based products and services. For foreign researchers and companies looking to source, study, or commercialize Indonesian natural products, that combination of documented biodiversity data and an on-the-ground research and regulatory network is difficult to replicate from outside the country.

Open for Partnership

SciencePreneur is open to partnership, joint ventures, and collaboration discussions with international investors, laboratories, and life science companies interested in Indonesian biodiversity research — from sourcing and dereplication to ABS-compliant partnership structuring and product commercialization.

Start of the series: Life Sciences Industry Landscape in Indonesia →